Navigation Links
Amylin Pharmaceuticals Reports 2010 Financial Results
Date:1/26/2011

is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA or SYMLIN, and the revenues generated from these products, may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results, may not be predictive of real world use or may not achieve desired end-points; risks that the results of the retrospective study mentioned in this press release will not be predictive of future use; risks that the CMC section of the metreleptin BLA mentioned in this press release may not be submitted in a timely fashion or that the BLA will not receive regulatory approval; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates, such as the BYDUREON NDA, or sNDAs for label expansion requests, such as the sNDA mentioned in this press release, may not be submitted timely or recei
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amylin Pharmaceuticals to Webcast Year-End Financial Results
2. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
4. Amylin Pharmaceuticals Reports Third Quarter Financial Results
5. Amylin Pharmaceuticals to Present at the 2010 Credit Suisse Healthcare Conference
6. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
7. Amylin Pharmaceuticals to Webcast Third Quarter Results
8. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
9. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
10. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
11. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... SAN FRANCISCO, Calif., May 16, 2012  Rigel Pharmaceuticals, Inc., ... franchise by focusing on two innovative, comprehensive treatment alternatives ... an inhaled SYK inhibitor, will be entering a Phase ... moderate asthmatic patients. The other, R256, an inhaled IL13 ...
... May 15, 2012   OphthaliX (OTCBB: OPLI) today ... ended March 31, 2012. OphthaliX is an advanced clinical-stage ... treatment of ophthalmic disorders.  Our drug, CF101 (known generically ... indications: dry eye syndrome; glaucoma and uveitis. We are ...
Cached Medicine Technology:Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 2Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 3Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 4OphthaliX Reports First Quarter 2012 Financial Results 2OphthaliX Reports First Quarter 2012 Financial Results 3
(Date:11/28/2014)... 27, 2014 (HealthDay News) -- Celebration can quickly ... on Thanksgiving Day, experts say. Over the last ... have occurred while people were using turkey fryers, according ... have actually cared for a patient who tried to ... be done in any circumstances," Dr. Arthur Sanford, a ...
(Date:11/28/2014)... Not only is the Éminence Organic ... petroleum, parabens and other cancer-causing agents, but they are ... and awareness programs that help in the fight against ... raised an incredible, record-breaking contribution of $30,000 through participation ... the Sweet Red Rose Whip Moisturizer and the company’s ...
(Date:11/28/2014)... 2014 Earlier in the year, ... hugely popular, 2014 MTV Video Music Awards broadcasted ... ground-breaking celebrity centered television advertisements directed at 11.9 ... were estimated by Entertainment Weekly and ... spotlight on celebrities photographed by paparazzi smoking. In ...
(Date:11/28/2014)... A newly released article from Community Health Center ... that will soon be spreading across the United States during ... a brief explanation of what the influenza virus is and ... under the age of 5, adults over the age of ... and lung diseases, asthma, or diabetes, are at higher risk ...
(Date:11/28/2014)... Patten Pecans, based in Lakeland, Georgia, loves ... driving them, they've added a pecan oil to their ... oils, they've found this pecan oil from Oliver ... retaining the buttery pecan notes that are in the ... found in pecans nuts is found in pecan oil, ...
Breaking Medicine News(10 mins):Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2
... Reporter , THURSDAY, Feb. 24 (HealthDay News) -- While experts ... of centuries past, isolated cases still appear, even in the ... report, a American lab worker died from plague in 2009 ... since 1959 and the first known death from a weakened ...
... men with a rapid rise in PSA have a biopsy ... and the PSA is within the "normal" range. But change ... of prostate cancer, and may lead to many unnecessary biopsies, ... Journal of the National Cancer Institute. Researchers ...
... , THURSDAY, Feb. 24 (HealthDay News) -- A mouse heart ... organ a day after birth, scientists report. With this ... can be found to help the human heart heal itself. ... regeneration, but they,re somehow permanently switched off," said Eric Olson, ...
... Full-term pregnancy has long been associated with a reduced risk ... more times a woman gives birth, the higher her risk ... subtype of the disease. Conversely, women who never give birth ... which has a poorer prognosis than other types of breast ...
... , THURSDAY, Feb. 24 (HealthDay News) -- People are more likely ... Researchers gave a 15-question math test to two groups of ... answers. One group was told that a software problem would ... they hit the space bar, but only they would know if ...
... EAST LANSING, Mich. Michigan State University has ... and food security in Mozambique through increasing the ... enhancing nutrition. The four-year grant, funded by ... to MSU and the University of Florida. The ...
Cached Medicine News:Health News:Plague Kills U.S. Lab Worker 2Health News:Plague Kills U.S. Lab Worker 3Health News:PSA velocity screening for prostate cancer may lead to unnecessary biopsies 2Health News:Scientists Say Newborn Mice Can Regrow Damaged Hearts 2Health News:Multiple childbirth linked to increased risk of rare, aggressive 'triple-negative' breast cancer 2Health News:Multiple childbirth linked to increased risk of rare, aggressive 'triple-negative' breast cancer 3Health News:People More Likely to Act Morally Than They Imagine 2Health News:$7.9 million grant to improve food security, nutrition in Mozambique 2
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
Duraloc acetabular cup system....
... acetabular cup system has been designed to ... tri-spiked and cluster hole configurations. The objective ... micromotion on three primary modes: Tilt, migration ... features result in initial and long-term fixation. ...
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
Medicine Products: